William Bernal

William Bernal

Auto-generated profile, based on publicly available information

William Bernal

Liver Intensive Therapy Unit, Institute of Liver Studies, King's College Hospital, London, United Kingdom

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2010 in The Lancet
Verified
Journal Article
Closed access
WBWilliam Bernal
William Bernal
GAGeorg Auzinger
Georg Auzinger
ADAnil Dhawan
Anil Dhawan
JWJulia Wendon
Julia Wendon

1 December 2007 in Hepatology
Verified
Journal Article
Open access
PDF file
WBWilliam Bernal
William Bernal
CHCatherine Hall
Catherine Hall
CKConstantine J. Karvellas
Constantine J. Karvellas
GAGeorg Auzinger
Georg Auzinger
ESElizabeth Sizer
Elizabeth Sizer
JWJulia Wendon
Julia Wendon
High circulating ammonia concentrations are common in patients with acute liver failure (ALF) and are associated with hepatic encephalopathy (HE) and intracranial hypertension (ICH). Other risk factors are poorly characterized. We evaluated the relation of the admission arterial ammonia concentration and other clinical variables with the development of HE and ICH. Arterial ammonia was measured on admission to the intensive care unit in 257 patients; 165 had ALF and severe HE, and there were 3 control groups: acute hepatic dysfunction without severe HE (n = 50), chronic liver disease (n = 33), and elective surgery (n = 9). Variables associated with ICH and HE were investigated with regression analysis. Ammonia was higher in ALF patients than controls. An independent risk factor for the development of severe HE and ICH, a level greater than 100 μmol/L predicted the onset of severe HE with 70% accuracy. The model for end-stage liver disease (MELD) score was also independently predictive of HE, and its combination with ammonia increased specificity and accuracy. ICH developed in 55% of ALF patients with a level greater than 200 μmol/L, although this threshold failed to identify most cases. After admission, ammonia levels remained high in those developing ICH and fell in those who did not. Youth, a requirement for vasopressors, and renal replacement therapy were additional independent risk factors. Conclusion: Ammonia is an independent risk factor for the development of both HE and ICH. Additional MELD scoring improved the prediction of HE. Factors other than ammonia also appear important in the pathogenesis of ICH. Ammonia measurements could form part of risk stratification for HE and ICH, identifying patients for ammonia-lowering therapies and invasive monitoring. (Hepatology 2007.)

1 July 2013 in Journal of Hepatology
Verified
Journal Article
Closed access
WBWilliam Bernal
William Bernal
AHAnna Hyyrylainen
Anna Hyyrylainen
AGAmit Gera
Amit Gera
VAVinod K. Audimoolam
Vinod K. Audimoolam
MMMark J.W. McPhail
Mark J.W. McPhail
RWRoger Williams
Roger Williams

1 April 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
RMRichard Moreau
Richard Moreau
JCJoan Clària
Joan Clària
FAFerran Aguilar
Ferran Aguilar
FFFrançois Fenaille
François Fenaille
JLJuan Jose Lozano
Juan Jose Lozano
PAPaolo Angeli
Paolo Angeli

1 October 2015 in The Lancet
Verified
Journal Article
Closed access
WBWilliam Bernal
William Bernal
RJRajiv Jalan
Rajiv Jalan
AQAlberto Quaglia
Alberto Quaglia
KSKenneth Simpson
Kenneth Simpson
JWJulia Wendon
Julia Wendon
ABAndrew Burroughs
Andrew Burroughs

1 May 2021 in Journal of Hepatology
Verified
Journal Article
Open access
JTJonel Trebicka
Jonel Trebicka
JFJavier Fernandez
Javier Fernandez
MPMária Papp
Mária Papp
PCPaolo Caraceni
Paolo Caraceni
WLWim Laleman
Wim Laleman
OÖOsman Cavit Özdogan
Osman Cavit Özdogan
Acute decompensation (AD) of cirrhosis may present without acute-on-chronic liver failure (ACLF) (AD-No ACLF), or with ACLF (AD-ACLF), defined by organ failure(s). Herein, we aimed to analyze and characterize the precipitants leading to both of these AD phenotypes. The multicenter, prospective, observational PREDICT study (NCT03056612) included 1,273 non-electively hospitalized patients with AD (No ACLF = 1,071; ACLF = 202). Medical history, clinical data and laboratory data were collected at enrolment and during 90-day follow-up, with particular attention given to the following characteristics of precipitants: induction of organ dysfunction or failure, systemic inflammation, chronology, intensity, and relationship to outcome. Among various clinical events, 4 distinct events were precipitants consistently related to AD: proven bacterial infections, severe alcoholic hepatitis, gastrointestinal bleeding with shock and toxic encephalopathy. Among patients with precipitants in the AD-No ACLF cohort and the AD-ACLF cohort (38% and 71%, respectively), almost all (96% and 97%, respectively) showed proven bacterial infection and severe alcoholic hepatitis, either alone or in combination with other events. Survival was similar in patients with proven bacterial infections or severe alcoholic hepatitis in both AD phenotypes. The number of precipitants was associated with significantly increased 90-day mortality and was paralleled by increasing levels of surrogates for systemic inflammation. Importantly, adequate first-line antibiotic treatment of proven bacterial infections was associated with a lower ACLF development rate and lower 90-day mortality. This study identified precipitants that are significantly associated with a distinct clinical course and prognosis in patients with AD. Specific preventive and therapeutic strategies targeting these events may improve outcomes in patients with decompensated cirrhosis. Acute decompensation (AD) of cirrhosis is characterized by a rapid deterioration in patient health. Herein, we aimed to analyze the precipitating events that cause AD in patients with cirrhosis. Proven bacterial infections and severe alcoholic hepatitis, either alone or in combination, accounted for almost all (96-97%) cases of AD and acute-on-chronic liver failure. Whilst the type of precipitant was not associated with mortality, the number of precipitant(s) was. This study identified precipitants that are significantly associated with a distinct clinical course and prognosis of patients with AD. Specific preventive and therapeutic strategies targeting these events may improve patient outcomes.